Hillevax
IPOXOMA Royalty – A biotech royalty aggregator
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- hillevax.com
- Total Funding
- $136.3M
- Last Round
- $135.0M Series DSep 2021
- Rounds
- 2
- Type
- Public
About
HilleVax is a clinical-stage biopharmaceutical company focused on developing vaccines. Lead program HIL-214 is a bivalent VLP vaccine candidate for moderate-to-severe acute gastroenteritis from norovirus in infants. Founded 2021, HQ Boston. Raised $136M. Phase 2b trial showed limited efficacy 2024. Website now redirects to XOMA Royalty.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
May 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...